-
[show abstract]
[hide abstract]
ABSTRACT: Human health risk to infants/toddlers and adults was evaluated based on two exposure scenarios from compact fluorescent lamp (CFL) breakage; first in a room with no ventilation and no clean-up, and second in a room with adequate ventilation and clean-up. Concentration data from multiple exposure scenarios tested in a study by Stahler et al. (2008) were compared to human toxicity benchmarks to calculate hazard quotients. For the no clean-up scenario, hazard quotients were generally less than 1, suggesting an unlikely health risk. When the room was ventilated and the broken CFL was cleaned-up, mercury concentrations were generally lower. A review of release scenarios, along with duration-adjusted toxicity benchmarks, indicated that few releases produced levels of concern, but some scenarios resulted in exceedance of risk targets and require further study. Uncertainties in this screening characterization include assumptions about room size, ventilation, age of lamp, the distribution of mercury in the room, and also the choice of the toxicity benchmarks used to develop the hazard quotients.
Regulatory Toxicology and Pharmacology 11/2011; 62(3):542-52. · 2.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In 1998 a panel of experts met to discuss the data available on chlorpyrifos, both human and animal, and to determine the most appropriate endpoints to be used for the derivation of the reference dose (RfD). Since that time, additional data have become available on chlorpyrifos from an experimental study involving humans. Moreover, Food Quality Protection Act (FQPA) considerations need to be addressed, and the appropriate cholinesterase endpoint, whether plasma, red blood cell, peripheral nerve, or brain, has become highly debated. Therefore, Dow AgroSciences, one of the manufacturers of chlorpyrifos, convened a second panel of toxicology and medical experts on June 21, 1999, to consider the presently available scientific literature both published and unpublished on chlorpyrifos and to determine the acute and chronic toxicological RfDs for chlorpyrifos. Four questions were posed to this second panel of experts concerning the available data on chlorpyrifos. (1) Should the RfD for chlorpyrifos be based on acetylcholinesterase (AChE) inhibition or butyrylcholinesterase (BuChE) inhibition as an endpoint for adverse effect? (2) Should the RfDs for chlorpyrifos be based on the data set from three human studies, which are supported by animal data? (3) Should the FQPA safety factor be reduced to 1xbased on animal studies of pre- or postnatal toxicity? (4) If an RfD for chlorpyrifos were to be based on animal data, then is a 10-fold interspecies uncertainty factor necessary? The panel of experts concluded that: (1) inhibition of BuChE is not an adverse effect, and the RfD for chlorpyrifos should be based on AChE inhibition; (2) the RfD for chlorpyrifos should be based on the three available human studies, which are also supported by animal data; (3) the extra FQPA safety factor should be reduced to 1x, because chlorpyrifos shows no pre- or postnatal toxicity of concern at relevant human exposure conditions; and (4) the extra 10-fold safety factor for interspecies variation appears overly conservative because no differences in species sensitivity to chlorpyrifos is evident.
Regulatory Toxicology and Pharmacology 05/2001; 33(2):110-6. · 2.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A holistic risk assessment (HRA) strategy is proposed as an alternative, inclusive paradigm which builds upon the traditional risk assessment process described by the National Academy of Sciences. This proposed process expands beyond the traditional process in that it: (i) includes parallel and integrated assessments for ecological risk and human health risks; (ii) recognizes the presence of competing risks that may arise from implementation of risk management decisions; (iii) is an iterative and nonsequential process that highlights the importance of risk characterization and the need for comparisons; (iv) has focus on presenting a series of risk choices that take into consideration parameters specific to exposed populations and ecosystems; and (v) involves communication as the first step between risk assessors and risk managers, with subsequent communication of the results of the assessment to clients and the public. This HRA strategy is illustrated by a case study on methyl mercury. Specific research is proposed for future improvements in this area.
Regulatory Toxicology and Pharmacology 11/1995; 22(2):110-7. · 2.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: For many years the concept of the "acceptable daily intake" has served the toxicological and regulatory fields quite well. However, as approaches to assessing the health significance of exposures to noncarcinogenic substances receive greater scrutiny, some difficulties with this traditional approach have become more apparent. Consequently, the concept of the "reference dose" is introduced in order to avoid use of prejudicial terms (e.g., "safety" and "acceptable"), to promote greater consistency in the assessment of noncarcinogenic chemicals, and to maintain the functional separation between risk assessment and risk management.
Regulatory Toxicology and Pharmacology 01/1989; 8(4):471-86. · 2.43 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A holistic risk assessment (HRA) strategy is proposed as an alternative, inclusive paradigm which builds upon the traditional risk assessment process described by the National Academy of Sciences. This proposed process expands beyond the traditional process in that it: (i) includes parallel and integrated assessments for ecological risk and human health risks; (ii) recognizes the presence of competing risks that may arise from implementation of risk management decisions; (iii) is an iterative and nonsequential process that highlights the importance of risk characterization and the need for comparisons; (iv) has focus on presenting a series of risk choices that take into consideration parameters specific to exposed populations and ecosystems; and (v) involves communication as the first step between risk assessors and risk managers, with subsequent communication of the results of the assessment to clients and the public. This HRA strategy is illustrated by a case study on methyl mercury. Specific research is proposed for future improvements in this area.
Regulatory Toxicology and Pharmacology.
